Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line

NCT05088889 is registered in ClinicalTrials.gov with Sheba Medical Center as lead sponsor.

NCT NCT05088889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05088889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line
Lead sponsor
Sheba Medical Center
Phase
Phase 1
Overall status
Unknown status
Start date
January 25, 2022
Completion date
July 1, 2024
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

stage iv pancreatic cancer